Difference between revisions of "Mitapivat (Pyrukynd)"
Jump to navigation
Jump to search
m |
|||
| Line 10: | Line 10: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *2022-02-17: Initial approval to treat hemolytic anemia (a disorder in which red blood cells are destroyed faster than they can be made) in adults with pyruvate kinase (PK) deficiency. ''(Based on ACTIVATE & ACTIVATE-T) | + | *2022-02-17: Initial approval to treat hemolytic anemia (a disorder in which red blood cells are destroyed faster than they can be made) in adults with [[Pyruvate kinase deficiency|pyruvate kinase (PK) deficiency]]. ''(Based on ACTIVATE & ACTIVATE-T) |
| + | |||
==Also known as== | ==Also known as== | ||
*'''Code name:''' AG-348 | *'''Code name:''' AG-348 | ||
Revision as of 09:58, 31 March 2024
Mechanism of action
Pyruvate kinase activator
Diseases for which it is used
Beta thalassemia
- AG348-C-010: Kuo KHM, Layton DM, Lal A, Al-Samkari H, Bhatia J, Kosinski PA, Tong B, Lynch M, Uhlig K, Vichinsky EP. Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study. Lancet. 2022 Aug 13;400(10351):493-501. link to original article PubMed NCT03692052
Pyruvate kinase deficiency
- AG348-C-003: Grace RF, Rose C, Layton DM, Galactéros F, Barcellini W, Morton DH, van Beers EJ, Yaish H, Ravindranath Y, Kuo KHM, Sheth S, Kwiatkowski JL, Barbier AJ, Bodie S, Silver B, Hua L, Kung C, Hawkins P, Jouvin MH, Bowden C, Glader B. Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency. N Engl J Med. 2019 Sep 5;381(10):933-944. link to original article PubMed NCT02476916
History of changes in FDA indication
- 2022-02-17: Initial approval to treat hemolytic anemia (a disorder in which red blood cells are destroyed faster than they can be made) in adults with pyruvate kinase (PK) deficiency. (Based on ACTIVATE & ACTIVATE-T)
Also known as
- Code name: AG-348
- Brand name: Pyrukynd